Les essais cliniques adoptent l’IA, l’intégration des données en vie réelle et la transformation numérique des protocoles

Les outils d’IA et les technologies numériques permettent une surveillance en temps réel, une sélection plus rapide des centres et une allocation plus efficiente des ressources dans les essais cliniques. La revue continue des données peut aider les promoteurs à identifier plus tôt les centres sous-performants et à réaffecter les ressources afin d’améliorer l’efficacité du recrutement, avec la possibilité de réduire significativement les coûts et d’accélérer les délais.

Thermo Fisher Scientific a conclu une collaboration stratégique avec Datavant afin d’étendre l’interopérabilité des données en vie réelle (real-world data) tout en préservant la confidentialité à travers les programmes de recherche clinique. Dans le cadre de cet accord, l’activité de recherche clinique PPD de Thermo Fisher intégrera la technologie de tokenisation et de connectivité des données de Datavant pour permettre le chaînage sécurisé de jeux de données patients au niveau individuel, désidentifiés, entre les essais, les registres et les études observationnelles. Les entreprises indiquent que ce partenariat vise à soutenir la génération sur mesure de preuves en vie réelle (real-world evidence), à améliorer les stratégies de recrutement et à réduire les frictions opérationnelles sur l’ensemble du cycle de vie de la recherche.

eClinical platforms are evolving toward protocol-driven eSource tools that standardize data collection at the site level. By translating study protocols into structured templates with built-in validation and edit checks, sponsors can improve data quality at the point of care while still allowing flexibility for site-specific workflows.

AI can play a meaningful role in data capture when paired with clear risk assessment and human-in-the-loop oversight. While straightforward API-based data pipelines between site and sponsor systems carry minimal risk, AI can add value once those connections are established by automating quality checks and identifying anomalies. The continued importance of advancing EHR integration and eSource to improve ALCOA compliance, structured data capture, and remote monitoring capabilities was also emphasized.

Insights from the 2026 SCOPE conference highlight a broader shift from document-based processes to connected, data-centric ecosystems. Advances such as digital protocols, interoperable data standards, and cross-sponsor data sharing are enabling more efficient study start-up, improved site selection, and more reliable patient experience data across the trial lifecycle.

A peer-reviewed analysis of the Diuretic Comparison Project within the US Department of Veterans Affairs found that nearly 70% of invited primary care providers agreed to participate, supporting enrollment and randomization workflows. More than 13,500 patients were successfully randomized, representing 82% of those who consented to the study. The findings also showed that low-burden integration with routine care and clear provider communication helped sustain engagement throughout the trial.

During a SCOPE panel on diversity in clinical trials, leaders from UCB, Takeda, Bristol Myers Squibb, Pfizer, and Merck stressed that meaningful progress requires deeper community engagement and operational flexibility. Panelists highlighted the need to move beyond digital outreach toward boots-on-the-ground engagement, invest in trial-naive sites, and tailor strategies to the unique needs of each community. Speakers also cautioned that fear of discussing diversity could stall progress, underscoring that scientific excellence depends on representative trial populations.

Roche has discontinued its Phase II SHIELD DMD study evaluating satralizumab, underscoring increasing execution risk in rare disease trials. Despite no new safety or efficacy concerns, limited recruitment and challenges generating regulatory-grade data led to the decision, highlighting how operational feasibility and evidentiary expectations are becoming key determinants of trial viability.

Leadership changes at the US Department of Health and Human Services have elevated CMS official Chris Klomp to oversee department operations while continuing his Medicare leadership roles. The restructuring is intended to strengthen coordination across agencies and support policy priorities, including drug pricing reforms and regulatory initiatives. Officials said the changes also reflect growing federal focus on healthcare affordability and operational oversight.